Active Biotech AB (publ) (LON:0GQU)

Market Cap	11.83M +2.1%
Revenue (ttm)	n/a
Net Income	-3.01M
EPS	-0.24
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,568
Open	5.98
Previous Close	6.06
Day's Range	5.98 - 6.08
52-Week Range	0.04 - 6.08
Beta	1.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The ...

• Industry: Pharmaceutical Preparations
• Founded: 1983
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GQU

Financial Performance

Financial numbers in SEK